市場調查報告書

溶□體疾病市場(2020-2026)

Lysosomal Storage Disease Market 2020-2026

出版商 Orion Market Research Pvt Ltd 商品編碼 949614
出版日期 內容資訊 英文
商品交期: 2-3個工作天內
價格
溶□體疾病市場(2020-2026) Lysosomal Storage Disease Market 2020-2026
出版日期: 2020年06月18日內容資訊: 英文
簡介

預計在預測期內(020-2026年),溶□體疾病市場將以顯著的複合年增長率增長。市場增長的驅動因素是疾病診斷率,疾病意識和醫療保健行業研發的增加。由於症狀因人而異,因此醫生難以診斷疾病,但是隨著研究和開發的增加,疾病的診斷也在改善。有專門的溶□體疾病實驗室可以執行特定的測試以診斷疾病。這也推動了市場的增長。

溶□體疾病市場根據類型和治療細分。市場按類型劃分為高雪氏病,龐貝氏病,Tay-Sachs病,法布裡氏病和其他(胱氨酸病和克拉夫病)。另一方面,通過療法,市場被分為□替代療法,底物減少療法和乾細胞移植。從地理上講,該市場分為北美,歐洲,亞太地區和其他地區。預計北美在溶□體疾病市場中佔有重要佔有率。

Actelion Pharmaceuticals, Ltd. (Johnson & Johnson Service, Inc.的子公司)、BioMarin Pharmaceuticals, Inc、Eli Lilly Co.、Horizon Therapeutics, Inc.、Leadiant Biosciences, Inc.、Pfizer, Inc.、Sanofi S.A、Takeda Pharmaceuticals Co. Ltd. 是溶□體疾病市場的領導者。這些公司正在擴大研究範圍,以尋找溶□體疾病的治療方法。此外,這些市場參與者正在積極採用增長戰略,例如併購,合夥關係以及對研發活動的投資,以在全球溶□體疾病市場中保持競爭力。

該報告調查了溶□體疾病市場,並概述了市場,市場增長因素和障礙因素的分析,市場規模趨勢以及按類型,治療方法和地區,競爭格局,主要公司概況,我們提供系統的信息,例如市場機會。

內容

第1章報告概述

第2章市場概述和見解

  • 調查範圍
  • 分析師見解和當前市場趨勢
  • 規則與規定

第3章競爭情況

  • 公司佔有率分析
  • 主要策略分析
  • 主要公司分析
    • Pfizer, Inc.
    • Sanofi S.A.
    • Actelion Pharmaceuticals, Ltd.
    • Horizon Therapeutics, Inc.
    • Takeda Pharmaceuticals Co. Ltd.

第4章市場決定因素

  • 動機
  • 抑制因子
  • 市場機會

第5章市場細分

  • 按類型
    • 高雪氏病
    • 龐貝病
    • 薩克斯病
    • 法布裡病
    • 其他(胱氨酸症,克拉伯病)
  • 按治療
    • □替代療法
    • 減少底物治療
    • 幹細胞移植

第6章區域分析

  • 北美
    • 美國
    • 加拿大
  • 歐洲
    • 英國
    • 德國
    • 意大利
    • 西班牙
    • 法國
    • 其他歐洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 其他亞太地區
  • 其他地區

第7章公司簡介

  • Actelion Pharmaceuticals, Ltd. (A Part of Johnson & Johnson Service, Inc.)
  • Alexion Pharmaceuticals, Inc.
  • Amicus Therapeutics, Inc.
  • AMO Pharma, Ltd.
  • Arena Pharmaceuticals, Inc.
  • BioMarin Pharmaceuticals, Inc.
  • ChiesiFarmaceuticiSpA
  • Eli Lilly Co.
  • Horizon Therapeutics, Inc.
  • Leadiant Biosciences, Inc.
  • Pfizer, Inc.
  • ProtalixBioTherapeutics, Inc.
  • Sanofi S.A.
  • Sigilon Therapeutics, Inc.
  • Takeda PharmaceuticalsCo.Ltd.
目錄
Product Code: OMR2021933

Global Lysosomal Storage Disease Market Size, Share & Trends Analysis Report by Type (Gaucher Disease, Pompe Disease, Tay-Sachs Disease, Fabry Disease, and Other (Cystinosis and Krabbe Disease)) by Treatment (Enzyme Replacement Therapy, Substrate Reduction Therapy, and Stem Cell Transplant) Forecast Period 2020-2026

Thelysosomal storage disease market is projected to grow at a considerable CAGR during the forecast period (2020-2026). The factors driving the growth of the market include the increasing rate of diagnosis of the disease, awareness about the disease and research and development in the healthcare sector. The diagnosis of the disease is difficult for physicians due to the variation of symptoms for different individuals. With more research and development going on, there is an improvement in the diagnosis of the disease. There are specialized lysosomal storage disease laboratories in which specific tests can be performed to diagnose the disease. This is fueling the growth of the market.

The lysosomal storage disease market is segmented on the basis of type and treatment. Based on the type, the market is segmented into Gaucher Disease, Pompe Disease, Tay-Sachs Disease, Fabry Disease, and other (Cystinosis and Krabbe Disease). Whereas, based on the treatment, the market is segmented into enzyme replacement therapy, substrate reduction therapy, and stem cell transplant. Geographically market is segmented into North America, Europe, Asia Pacific and the Rest of the World. North America is anticipated to hold a considerable share in the lysosmal storage disease market.

Actelion Pharmaceuticals, Ltd. (A Part of Johnson & Johnson Service, Inc.), BioMarin Pharmaceuticals, Inc, Eli Lilly Co., Horizon Therapeutics, Inc., Leadiant Biosciences, Inc., Pfizer, Inc., Sanofi S.A, and Takeda Pharmaceuticals Co. Ltd. among others are the key players operating in the lysosomal Storage disease market. These companies are expanding their researches to find a treatment for the lysosomal storage disease. Moreover, these market players are actively adopting growth strategies such as mergers and acquisitions, partnerships, investment in R&D activities among others to remain competitive in the global lysosomal storage disease market.

Research Methodology

The market study of the global lysosomal storage disease market is incorporated by extensive primary and secondary research conducted by the research team at OMR. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.

Secondary Sources Include:

  • Financial reports of companies involved in the market.
  • Whitepapers, research-papers, and news blogs.
  • Company websites and their product catalog.

The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation

1. Global Lysosomal Storage Disease Market Research and Analysis by Type

2. Global Lysosomal Storage Disease Market Research and Analysis byTreatment

The Report Covers:

  • Comprehensive research methodology of the global lysosomal storage disease market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the global lysosomal storage disease market.
  • Insights about market determinants which are stimulating the global lysosomal storage disease market.
  • Detailed and extensive market segments with regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.

Table of Contents

1. Report Summary

  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Geography

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion
  • 2.3. Rules & Regulations

3. Competitive Landscape

  • 3.1. Company Share Analysis
  • 3.2. Key Strategy Analysis
  • 3.3. Key Company Analysis
    • 3.3.1. Pfizer, Inc.
      • 3.3.1.1. Overview
      • 3.3.1.2. Financial Analysis
      • 3.3.1.3. SWOT Analysis
      • 3.3.1.4. Recent Developments
    • 3.3.2. Sanofi S.A.
      • 3.3.2.1. Overview
      • 3.3.2.2. Financial Analysis
      • 3.3.2.3. SWOT Analysis
      • 3.3.2.4. Recent Developments
    • 3.3.3. Actelion Pharmaceuticals, Ltd.
      • 3.3.3.1. Overview
      • 3.3.3.2. Financial Analysis
      • 3.3.3.3. SWOT Analysis
      • 3.3.3.4. Recent Developments
    • 3.3.4. Horizon Therapeutics, Inc.
      • 3.3.4.1. Overview
      • 3.3.4.2. Financial Analysis
      • 3.3.4.3. SWOT Analysis
      • 3.3.4.4. Recent Developments
    • 3.3.5. Takeda Pharmaceuticals Co. Ltd.
      • 3.3.5.1. Overview
      • 3.3.5.2. Financial Analysis
      • 3.3.5.3. SWOT Analysis
      • 3.3.5.4. Recent Developments

4. Market Determinants

  • 4.1 Motivators
  • 4.2 Restraints
  • 4.3 Opportunities

5. Market Segmentation

  • 5.1. Global Lysosomal Storage Disease Market by Type
    • 5.1.1. GaucherDisease
    • 5.1.2. Pompe Disease
    • 5.1.3. Tay-SachsDisease
    • 5.1.4. Fabry Disease
    • 5.1.5. Other (Cystinosis and Krabbe Disease)
  • 5.2. Global Lysosomal Storage Disease Market by Treatment
    • 5.2.1. Enzyme Replacement Therapy
    • 5.2.2. Substrate Reduction Therapy
    • 5.2.3. Stem Cell Transplant

6. Regional Analysis

  • 6.1. North America
    • 6.1.1. United States
    • 6.1.2. Canada
  • 6.2. Europe
    • 6.2.1. UK
    • 6.2.2. Germany
    • 6.2.3. Italy
    • 6.2.4. Spain
    • 6.2.5. France
    • 6.2.6. Rest of Europe
  • 6.3. Asia-Pacific
    • 6.3.1. China
    • 6.3.2. India
    • 6.3.3. Japan
    • 6.3.4. Rest of Asia-Pacific
  • 6.4. Rest of the World

7. Company Profiles

  • 7.1. Actelion Pharmaceuticals, Ltd. (A Part of Johnson & Johnson Service, Inc.)
  • 7.2. Alexion Pharmaceuticals, Inc.
  • 7.3. Amicus Therapeutics, Inc.
  • 7.4. AMO Pharma, Ltd.
  • 7.5. Arena Pharmaceuticals, Inc.
  • 7.6. BioMarin Pharmaceuticals, Inc.
  • 7.7. ChiesiFarmaceuticiSpA
  • 7.8. Eli Lilly Co.
  • 7.9. Horizon Therapeutics, Inc.
  • 7.10. Leadiant Biosciences, Inc.
  • 7.11. Pfizer, Inc.
  • 7.12. ProtalixBioTherapeutics, Inc.
  • 7.13. Sanofi S.A.
  • 7.14. Sigilon Therapeutics, Inc.
  • 7.15. Takeda PharmaceuticalsCo.Ltd.

LIST OF TABLES

  • 1. GLOBAL LYSOSOMAL STORAGE DISEASE MARKET RESEARCH AND ANALYSIS BY TYPE, 2019-2026 ($ MILLION)
  • 2. GLOBAL GAUCHER DISEASE MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 3. GLOBAL POMPE DISEASE MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 4. GLOBAL TAY-SACHS DISEASE MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 5. GLOBAL FABRY DISEASE MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 6. GLOBAL OTHER MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 7. GLOBAL LYSOSOMAL STORAGE DISEASE MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2019-2026 ($ MILLION)
  • 8. GLOBAL ENZYME REPLACEMENT THERAPYMARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 9. GLOBAL SUBSTRATE REDUCTION THERAPYMARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 10. GLOBAL STEM CELL TRANSPLANTMARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 11. GLOBAL LYSOSOMAL STORAGE DISEASE MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2019-2026 ($ MILLION)
  • 12. NORTH AMERICAN LYSOSOMAL STORAGE DISEASE MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
  • 13. NORTH AMERICAN LYSOSOMAL STORAGE DISEASE MARKET RESEARCH AND ANALYSIS BY TYPE, 2019-2026 ($ MILLION)
  • 14. NORTH AMERICAN LYSOSOMAL STORAGE DISEASE MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2019-2026 ($ MILLION)
  • 15. EUROPEAN LYSOSOMAL STORAGE DISEASE MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
  • 16. EUROPEAN LYSOSOMAL STORAGE DISEASE MARKET RESEARCH AND ANALYSIS BY TYPE, 2019-2026 ($ MILLION)
  • 17. EUROPEAN LYSOSOMAL STORAGE DISEASE MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2019-2026 ($ MILLION)
  • 18. ASIA-PACIFIC LYSOSOMAL STORAGE DISEASE MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
  • 19. ASIA-PACIFIC LYSOSOMAL STORAGE DISEASE MARKET RESEARCH AND ANALYSIS BY TYPE, 2019-2026 ($ MILLION)
  • 20. ASIA-PACIFIC LYSOSOMALSTORAGE DISEASE MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2019-2026 ($ MILLION)
  • 21. REST OF THE WORLD LYSOSOMAL STORAGE DISEASE MARKET RESEARCH AND ANALYSIS BY TYPE, 2019-2026 ($ MILLION)
  • 22. REST OF THE WORLD LYSOSOMAL STORAGE DISEASE MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2019-2026 ($ MILLION)

LIST OF FIGURES

  • 1. GLOBAL LYSOSOMAL STORAGE DISEASEMARKET SHARE BY TYPE, 2019 VS 2026 (%)
  • 2. GLOBAL LYSOSOMAL STORAGE DISEASEMARKET SHARE BY TREATMENT, 2019 VS 2026 (%)
  • 3. GLOBAL LYSOSOMAL STORAGE DISEASEMARKET SHARE BY GEOGRAPHY, 2019 VS 2026 (%)
  • 4. US LYSOSOMAL STORAGE DISEASE MARKET SIZE, 2019-2026 ($ MILLION)
  • 5. CANADA LYSOSOMAL STORAGE DISEASE MARKET SIZE, 2019-2026 ($ MILLION)
  • 6. UK LYSOSOMAL STORAGE DISEASE MARKET SIZE, 2019-2026 ($ MILLION)
  • 7. FRANCE LYSOSOMAL STORAGE DISEASE MARKET SIZE, 2019-2026 ($ MILLION)
  • 8. GERMANY LYSOSOMAL STORAGE DISEASE MARKET SIZE, 2019-2026 ($ MILLION)
  • 9. ITALY LYSOSOMAL STORAGE DISEASE MARKET SIZE, 2019-2026 ($ MILLION)
  • 10. SPAIN LYSOSOMAL STORAGE DISEASE MARKET SIZE, 2019-2026 ($ MILLION)
  • 11. ROE LYSOSOMAL STORAGE DISEASE MARKET SIZE, 2019-2026 ($ MILLION)
  • 12. INDIA LYSOSOMAL STORAGE DISEASE MARKET SIZE, 2019-2026 ($ MILLION)
  • 13. CHINA LYSOSOMAL STORAGE DISEASE MARKET SIZE, 2019-2026 ($ MILLION)
  • 14. JAPAN LYSOSOMAL STORAGE DISEASE MARKET SIZE, 2019-2026 ($ MILLION)
  • 15. REST OF ASIA-PACIFIC LYSOSOMAL STORAGE DISEASE MARKET SIZE, 2019-2026 ($ MILLION)
  • 16. REST OF THE WORLD LYSOSOMAL STORAGE DISEASE MARKET SIZE, 2019-2026 ($ MILLION)